EyeBOX Concussion Assessment
Patented technology based on published research
Using ocular motility and other domains of brain function, the EyeBOX® device provides a BOX Score℠ to help clinicians determine the presence of concussion.
The EyeBOX device is the only concussion diagnosis technology based on published research on cranial nerve function and their relation to eye movements. Because Oculogica’s technology is based on function, rather than the patient’s “will”, its proprietary approach does not require baseline testing. This reduces time and the possibility of “gaming” the baseline test.
Why does FDA authorization matter?
“FDA warns public not to use unauthorized or uncleared medical devices, including smartphone apps, to help assess or diagnose a concussion.”
FDA Press Release
– April 10, 2019
“Products being marketed for the assessment, diagnosis, or management of a head injury, including concussion, that have not been authorized or cleared by the FDA are in violation of the law.”
M.D., J.D., director of the FDA’s Center for Devices and Radiological Health
– April 10, 2019,
Detailed information powers objective diagnosis
The EyeBOX device’s unique data collection capability is used in a proprietary algorithm that generates a BOX Score, an assessment which the FDA has authorized as an aid in the diagnosis of concussion, or mTBI. Each analysis is unique to each patient.
Research is ongoing in a number of areas important in concussion. EyeBOX technology may be useful for identifying those at risk for second impact syndrome (SIS), a rare but serious condition in which a second concussion occurs before a first concussion has properly healed, causing rapid and severe brain swelling.
The BOX Score may also enable healthcare providers to rule out concussion in cases such as neck injury or inner ear damage that have symptoms common to concussion, such as dizziness, headache and nausea.